Danimer Scientific Inc

Danimer Scientific — Q4 2023 Earnings Presentation

12 slides from Danimer Scientific's earnings presentation, Mar 28, 2024

  1. Slide 1: Fourth Quarter 2023 Earnings Presentation

    Fourth Quarter 2023 Earnings Presentation March 28, 2024

  2. Slide 2: Disclaimer and Forward-Looking Statements

    This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w

  3. Slide 3: Fast Facts

    FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 257 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer and developer of PH

  4. Slide 4: Commercial Updates and Customer Awards

    Previously announced cutlery award expected to require ~20 million pounds of annual volume of Nodax® cutlery resins; first shipments anticipated mid-year 2024. Opportunities for the above cutlery award poised to expand into new geographical regions and additional end-product categories. Delta Cafés

  5. Slide 5: Sales Cycle

    Lead Evaluation Pre-Commercial Launch Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample New leads are screened by sales first, then a joint committee with R&D & sales if necessary; many do not make it past this stage 1 – 5 Years 6 Months

  6. Slide 6: Sales Cycle (continued): Material Selection

    Material Selection ~ 85 customers currently in “Material Selection” zone. Material selection zone is an iterative process, not necessarily a linear process. Sales Cycle (continued) Material Selection Trials R&D / Product Development Certification Work Market Testing Regulatory Initial Sample 6

  7. Slide 7: Q4 and Full Year 2023 Financial Summary

    Q4 and Full Year 2023 Financial Summary FY23 sales overall decreased compared to FY22 driven by higher PHA sales of $1.8M, which did not fully offset lower PLA sales of ($6.1M) due to the impact of the Ukraine conflict. Increased adjusted gross loss primarily reflects increased fixed costs associate

  8. Slide 8: Fiscal 2024 Guidance Summary

    Adjusted EBITDA guidance range of $(22) million to $(32) million. Capital expenditures guidance range of $8 million to $10 million. Ending cash balance for fiscal 2024 in the range of $20 million to $25 million. Guidance reflects anticipated timing of revenues associated with customer product launch

  9. Slide 9: tess, ~ e

    AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company

  10. Slide 10: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation 10

  11. Slide 11: Adjusted Gross Profit Reconciliation

    Adjusted Gross Profit Reconciliation 11

  12. Slide 12: Thank You

    a danimer ~ scientific THANK YOU

Danimer Scientific — Q4 2023 Earnings Presentation on 6ix